



HAL
open science

Development and application of a questionnaire to assess patient beliefs in rheumatoid arthritis and axial spondyloarthritis

Laure Gossec, Francis Berenbaum, Pierre Chauvin, Christophe Hudry, Gabrielle Cukierman, Thibault de Chalus, Caroline Dreuillet, Vincent Saulot, Sabine Tong, Françoise Russo-Marie, et al.

► To cite this version:

Laure Gossec, Francis Berenbaum, Pierre Chauvin, Christophe Hudry, Gabrielle Cukierman, et al.. Development and application of a questionnaire to assess patient beliefs in rheumatoid arthritis and axial spondyloarthritis. *Clinical Rheumatology*, In press, 10.1007/s10067-018-4172-5 . hal-01826447

HAL Id: hal-01826447

<https://hal.sorbonne-universite.fr/hal-01826447>

Submitted on 29 Jun 2018

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

1 **Development and Application of a Questionnaire to Assess Patient**
2 **Beliefs in Rheumatoid Arthritis and Axial Spondyloarthritis**

3

4 Laure Gossec^{1,2}, Francis Berenbaum^{3,4}, Pierre Chauvin⁵, Christophe Hudry⁶, Gabrielle
5 Cukierman⁷, Thibault de Chalus⁷, Caroline Dreuillet⁸, Vincent Saulot⁸, Sabine Tong⁹,
6 Françoise Russo-Marie⁸, Jean-Michel Joubert⁷, Alain Saraux^{10,11}

7 ¹Sorbonne Universités, UPMC Univ Paris 06, INSERM, Institut Pierre Louis d'Epidémiologie et
8 de Santé Publique (UMRS 1136), GRC-UPMC 08 (EEMOIS), Paris, France; ²Service de
9 rhumatologie, Hôpital Pitié Salpêtrière, Paris, France; ³Sorbonne Universités, UPMC Univ Paris
10 06, INSERM, Paris, France; ⁴Department of Rheumatology, Hôpital Saint-Antoine, AP-HP,
11 Paris, France; ⁵Sorbonne Universités, UPMC Univ Paris 06, INSERM, Institut Pierre Louis
12 d'Epidémiologie et de Santé Publique (UMRS 1136), Department of Social Epidemiology,
13 Paris, France; ⁶Department of Rheumatology, Hôpital Cochin, AP-HP, Paris, France; ⁷UCB
14 Pharma, Colombes, France; ⁸Arthritis Fondation Courtin, Neuilly-Sur-Seine, France; ⁹AXONAL-
15 BIOSTATEM, Nanterre, France; ¹⁰Department of Rheumatology, CHU de la Cavale-Blanche,
16 Brest, France; ¹¹Université de Brest, INSERM, LabEx IGO, UMR1227, Lymphocytes B et
17 Autoimmunité, Brest, France

18 *Thibault de Chalus was an employee of UCB Pharma at the time of the study*

19 *Caroline Dreuillet was an employee of Arthritis Fondation Courtin at the time of the study*

20

21 **Correspondence to:** Laure Gossec, Service de rhumatologie, Hôpital Pitié
22 Salpêtrière, 47–83 Boulevard de l'Hôpital, 75013, Paris, France. Tel: +33 1 42 17 84
23 21; Fax: +33 42177959; Email: laure.gossec@aphp.fr

24 **Funding:** UCB Pharma and Fondation Arthritis

25

26

27

28

29

30 **ACKNOWLEDGEMENTS**

1 The authors thank the patients, the investigators and their teams who took part in
2 this study. The authors also acknowledge Susanne Wiegatz (UCB Pharma GmbH,
3 Monheim am Rhein, Germany) for publication coordination, and Sam Fraser, PhD
4 (Costello Medical, Cambridge, UK) for medical writing and editorial assistance in
5 preparing this manuscript for publication, based on the authors' input and direction.

6 The study was initiated and funded by the Fondation Arthritis and the Laboratoires
7 UCB France, who delegated operational management of the study to a contract
8 research organisation (AXONAL-BIOSTATEM, Nanterre, France).

9 **CONFLICT OF INTEREST**

10 LG, PC, CH, CD, ST and AS report non-financial support from UCB Pharma and
11 Fondation Arthritis during the conduct of the study; FB reports non-financial support
12 from UCB Pharma during the conduct of the study; GC and J-MJ are employees of
13 UCB Pharma; TdC was an employee of UCB Pharma at the time of the study; VS and
14 FR-M declare that they have no competing interest. The authors have full control of
15 all primary data and agree to allow the journal to review these data if requested.

1 **ABSTRACT**

2 ***Introduction/Objectives***

3 Misinterpretation of patient beliefs may complicate shared decision-making in
4 rheumatoid arthritis (RA) or axial spondyloarthritis (axSpA). The objective of this
5 study was to develop a questionnaire to assess patients' beliefs about their disease
6 and its treatment, and to identify patient characteristics associated with these beliefs.

7 ***Method***

8 All beliefs reported by >5% of 50 patients in a previous study were reformulated
9 with a partnering patient organization into statements with which participants could
10 rate their agreement on a scale of 0–10 (totally disagree to totally agree). The
11 resulting Questionnaire for Arthritis Dialogue (QuAD) was made available to patients
12 with RA or axSpA. A score ≥ 7 was considered a strongly-held belief. Associations
13 between patient characteristics and individual lifestyle beliefs were assessed using
14 multiple logistic regression.

15 ***Results***

16 The 21-item QuAD was completed by 672 patients (432 RA, 240 axSpA; mean [\pm SD]
17 age: 54.2 [\pm 14.2]; 63.7% female). The most widely held beliefs were related to
18 uncertainty about progression (n=354, 54.0%), heredity (n=309, 47.8%) and flare
19 triggers (n=283, 42.7%). The unwarranted belief that physical activity is deleterious
20 to disease activity was associated with markers of psychological distress and lower
21 educational levels.

22 ***Conclusions***

1 The beliefs of patients with RA or axSpA about their disease are wide-ranging. Since
2 these may be unwarranted and may lead to inappropriate behaviors, physicians
3 should discuss these beliefs with their patients. The QuAD may facilitate this
4 dialogue, and may also be useful in population studies to standardize the assessment
5 and evolution of beliefs over time.

6 **Key words**

7 Rheumatoid arthritis, outcome measures, spondyloarthritis, behavior, patient attitude
8 to health

9

10

11

1 **INTRODUCTION**

2 Chronic inflammatory rheumatic diseases (CIRDs), of which rheumatoid arthritis (RA)
3 and axial spondyloarthritis (axSpA) are the most frequent, are progressive diseases
4 that evolve with an unpredictable and fluctuating course over the patient's lifetime.

5 The chronic nature of these diseases, the heterogeneity of physical manifestations
6 between patients, and the difficulty in foreseeing disease flares and long-term
7 progression create uncertainty and stress for the patient. In addition, they make it
8 difficult for patients to develop a valid internal representation of their disease [1].

9 This may in turn lead to misplaced disease perceptions and treatment expectations
10 [2, 3], and the development of inappropriate behaviors for managing disease
11 manifestations and coping with their consequences [4, 5]. For example, patients who
12 believe that disease flares are triggered by physical activity may actively pursue a
13 sedentary lifestyle, with detrimental consequences for their CIRD and their general
14 health [6]. The erroneous assumption that diet has an impact on disease may also
15 lead the patient to make poor nutritional choices [7]. In addition, expectations about
16 the benefits and risks of treatment with disease-modifying antirheumatic drugs
17 (DMARDs) may influence treatment adherence [8] or perceptions of tolerability [9].

18 Therefore, it is important for physicians to understand their patients' beliefs about
19 their disease, and to initiate a dialogue with the patient about unwarranted beliefs,
20 with the goal of modifying behavior and thereby improving overall health. However,
21 very little research has been published relating to the beliefs and apprehensions of
22 patients with CIRDs [10].

23 In order to gain more information about disease perceptions in patients with CIRDs,
24 a research program was initiated, with the aim of developing a questionnaire to
25 evaluate these beliefs. The specific objectives of this study were to develop a

- 1 questionnaire to assess beliefs in patients with RA or axSpA regarding their disease
- 2 and its treatment, and to identify patient characteristics associated with these beliefs.
- 3

1 **MATERIALS AND METHODS**

2 **Development of the Questionnaire for Arthritis Dialogue**

3 A previous qualitative study of disease perception in patients with RA or axSpA was
4 performed in 50 patients (25 with RA and 25 with axSpA) [11]. Based on data from
5 this study [11], all items reported by >5% of patients were rephrased as assertions,
6 with help from a partnering patient organization. This questionnaire covered the
7 most widely-held perceptions about disease and treatment. Other questions related
8 to patient fears and beliefs are reported elsewhere [12]. Each item was scored on a
9 10-point numerical rating scale (NRS) ranging from 0 (totally disagree) to 10 (totally
10 agree).

11 The questions were tested in a sample of 10 patients for linguistic validation and
12 cognitive debriefing. The original French questionnaire was translated into English
13 through two independent forward translations (French to English) followed by two
14 independent back translations (English to French), with reconciliation of the
15 translated texts [13]. The questionnaire took around 25 minutes to complete.

16 **Application of the Questionnaire for Arthritis Dialogue to a wide sample**

17 This cross-sectional, prospective study included patients with RA or axSpA in
18 everyday practice in France, and was implemented by hospital and community
19 rheumatologists between July 2014 and October 2015. The study was performed in
20 accordance with Good Epidemiological Practice [14] and relevant French guidelines
21 for patient surveys. Verbal informed consent was obtained from all participating
22 patients. The study protocol was considered by the Ethics Committee of the St
23 Antoine Hospital, Paris, to be both ethical and outside the scope of French legislation
24 restricting biomedical research (session of 7th October 2014). The study was also

1 declared to the National Advisory Committee on Medical Research Information
2 (CCTIRS) and the French national data protection agency (CNIL).

3 All rheumatologists currently practicing in France were invited to participate in the
4 study though post and email. Each participating rheumatologist was expected to
5 invite all consecutive patients with RA or axSpA during routine outpatient visits who
6 fulfilled the eligibility criteria (up to 20 patients per investigator). Adult patients
7 (aged >18 years) with a diagnosis of RA according to the American College of
8 Rheumatology/European League Against Rheumatism (ACR/EULAR) classification
9 criteria [15], or of axSpA according to the Assessment in Spondyloarthritis
10 International Society (ASAS) classification criteria [16], were eligible and were
11 enrolled if they agreed to participate. Patients who were unable to complete a
12 questionnaire in French were excluded.

13 **Data collection**

14 Patients were asked to complete both the beliefs questionnaire and other questions
15 relating to fears (44 items in total) [12], the Hospital Anxiety and Depression Scale
16 (HADS) [17], the Arthritis Helplessness Index (AHI) [18], the Patient Global
17 Assessment (PGA) of overall disease activity (scored between 0–10), and for patients
18 with axSpA, the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) [19]. All
19 questionnaires were in French. Patients also provided information on
20 sociodemographic indicators, health insurance coverage and disease duration.

21 In parallel, rheumatologists provided information on their own age, gender, type of
22 practice (hospital, community or mixed) and geographical region, in addition to
23 information about the patient on current treatment, disease activity measured with
24 the 28-item Disease Activity Score calculated with erythrocyte sedimentation rate

1 (DAS28[ESR]) [20] for RA, and an overall assessment of disease activity scored from
2 0–10.

3 **Statistical analysis**

4 Data were analyzed for all patients for whom both patient and physician
5 questionnaires were available. For each item of the questionnaire, mean value \pm
6 standard deviation (SD) and the percentage of patients with scores ≥ 7 were
7 determined both for the total population, and for the RA and axSpA subgroups.
8 Comparisons were performed with the χ^2 test (corrected for continuity) or Fisher's
9 exact test, as appropriate. A score of ≥ 7 was taken to indicate strong agreement
10 with the opinion presented. This cut-off was chosen on an empirical basis; in the
11 absence of any known disease characteristic with which these beliefs are correlated,
12 we did not feel that it was realistic to attempt psychometric calibration of the VAS.

13 In order to identify variables associated with a score ≥ 7 for a given item, we
14 performed a univariate regression analysis for all patient and physician variables
15 documented in the study. Variables with an association at a probability threshold of
16 0.20 (χ^2 test) were entered into a backwards stepwise multiple logistic regression
17 analysis. A threshold of 0.05 was used for retention of variables in the model.

18 Multiple imputation methods (Markov chains using Monte Carlo simulations) were
19 used for missing data when this concerned $>5\%$ of all patients. When this proportion
20 was $\leq 5\%$, missing data were replaced with the median value of the full study
21 sample. All statistical analyses were performed using SAS® Version 9.2 (SAS
22 Institute, Cary, NC, USA).

23 **Role of the funding source**

1 UCB Pharma sponsored the study and the development of the manuscript and
2 reviewed the text to ensure that from a UCB Pharma perspective, the data presented
3 in the publication are scientifically, technically and medically supportable, that they
4 do not contain any information that has the potential to damage the intellectual
5 property of UCB Pharma, and that the publication complies with applicable laws,
6 regulations, guidelines and good industry practice. The authors approved the final
7 version to be published after critically revising the manuscript for important
8 intellectual content.

9

10

1 **RESULTS**

2 **Characteristics of the Questionnaire for Arthritis Dialogue**

3 The Questionnaire for Arthritis Dialogue (QuAD) includes 44 items in total, 21 of
4 which cover beliefs on the cause of disease, disease flares and treatments. The
5 remaining 23 items concern fears that are described in detail elsewhere. [21]

6 **Participants in the validation study**

7 Of the 1618 rheumatologists in France who were contacted, 134 agreed to
8 participate in the study (including 20 who were exclusively community-based, 51
9 exclusively hospital-based and 29 with a mixed practice), and 100 enrolled at least
10 one patient.

11 A total of 796 patients were enrolled, of whom 672 (84.4%) were available for
12 analysis (**Table 1**). The remaining patients were excluded, due to either missing
13 physician (n=98) or patient (n=12) questionnaires, or because the diagnostic criteria
14 for RA/axSpA were either not fulfilled (n=5) or not documented (n=10). The median
15 number of patients enrolled by each center was six. Patients with RA were more
16 frequently female, and older on average than those with axSpA. Both physician and
17 patient global assessments were higher for patients with axSpA than for those with
18 RA. In both groups, around three-quarters of patients were undergoing treatment
19 with biological DMARDs.

20 **Beliefs of patients with rheumatoid arthritis and axial spondyloarthritis**

21 The 21 relevant items in the QuAD (**Table 2**) included beliefs about psychological
22 factors (2 items), genetic factors (2 items), physical activity (4 items), diet (4 items),
23 and other lifestyle factors (3 items). The remaining items were categorized as
24 miscellaneous beliefs (6 items).

1 Mean (\pm SD) scores for each item of the QuAD ranged from 0.7 (\pm 1.6) for “I think
2 that drinking alcohol (even moderately) triggered my disease” to 6.3 (\pm 3.2) for “I
3 don't know how my disease will progress (and that worries me)”. The proportion of
4 patients rating each item of the QuAD with a score \geq 7 is presented in **Figure 1**.
5 Overall, beliefs appeared to be more strongly held in patients with axSpA than in
6 those with RA. The three most widely held beliefs were: “I don't know how my
7 disease will progress (and that worries me)” (n=354, 54.0%), “I am afraid of passing
8 my disease on to my children” (n=309, 47.8%), and “I think that my flare-ups are
9 triggered by fatigue” (n=283, 42.7%).

10 **Characteristics of patients with specific lifestyle beliefs**

11 A comprehensive listing of patient characteristics associated with individual lifestyle
12 beliefs, identified from the univariate and multivariate analyses, is provided in
13 **Online Resource 1** (physical activity items), **Online Resource 2** (food and diet
14 items) and **Online Resource 3** (other lifestyle items).

15 Findings from the multivariate analysis are presented in **Table 3**. The belief that
16 ‘eating certain foods could reduce disease flares’ had more acceptance in women
17 than in men. The belief that ‘physical activity could reduce disease flares’ had more
18 acceptance in patients with higher education, while fewer patients in this subgroup
19 believed that their disease may have been caused by physical overload. In contrast,
20 more patients with high HADS scores for anxiety or depression (or both) believed
21 that ‘their disease was caused by physical overload’ and that ‘flares were triggered
22 by physical effort’, whereas fewer held the opposite belief that ‘physical activity could
23 reduce flares’. Similarly, more patients with high AHI scores believed that disease
24 flares could be triggered by physical activity, or that their disease may have been
25 caused by environmental factors such as pollution. The belief that ‘drinking alcohol

1 or smoking caused the disease' was more widely accepted among financially
2 deprived patients (those eligible for an income subsidy from the state).

3 Some differences were observed between patients with RA and those with axSpA.
4 Compared to patients with RA, those with axSpA were more likely to believe that
5 taking physical exercise could reduce disease flares, and less likely to believe that
6 their disease was caused by smoking.

7 These multiple logistic regression analyses were reiterated twice: firstly, by
8 introducing age and gender as forced variables in the models, and then with patient-
9 reported disease activity (visual analogue scale, VAS) and disease duration as forced
10 variables. Although these adjustments altered the odds ratios minimally, the
11 variables retained in the models were not changed (data not shown).

1 **DISCUSSION**

2 The aim of this study was to develop a questionnaire to evaluate the beliefs of
3 patients with RA and axSpA, and to identify patient characteristics associated with
4 these beliefs. In a large sample of patients with RA or axSpA, our study identified a
5 wide range of patient opinions on their disease and its treatment, and a number of
6 demographic, socioeconomic and psychological factors associated with these
7 opinions.

8 No individual belief was strongly held by more than half of patients overall. However,
9 more than one-third of patients attributed their disease to psychological or genetic
10 causes, whereas less than ten percent attributed it to causes that have little support
11 from medical opinion, such as diet, pollution, smoking, infection, vaccination or
12 alcohol consumption. In contrast, beliefs about lifestyle and CIRDs were often
13 erroneous, perhaps due to inadequate patient education, or because of psychological
14 distress. These beliefs need to be explored by physicians and discussed with the
15 patient to ensure that the patient maintains as healthy a lifestyle as possible.

16 The diversity of beliefs identified include those that are consistent with current
17 medical opinion, such as the belief that axSpA may have a genetic cause; those that
18 are inconsistent with medical opinion, such as the belief that CIRDs may be caused
19 by vaccination, and those for which there is limited medical consensus or where
20 medical opinion is evolving. In general, the beliefs held were similar between
21 patients with RA and those with axSpA, which may be explained by the similarly
22 unpredictable course of the two diseases, the common core symptoms, and the fact
23 that these patients will usually be cared for in the same healthcare facilities and thus
24 be exposed to the same sources of information. However, patients with axSpA were
25 around twice as likely as those with RA to attribute their disease to a genetic origin,

1 likely reflecting awareness of a strong association between SpA and HLA-B27 [22].
2 In contrast, when asked to suggest possible causes for their disease, patients with
3 RA were more likely to cite emotional factors. Moreover, patients with axSpA, who
4 were on average younger and had a higher level of education than those with RA,
5 were more likely to believe that physical activity could be beneficial to their disease
6 (in agreement with current medical thinking) and less likely to believe that their
7 disease was caused by smoking.

8 In this study, we focused on beliefs relating to lifestyle. This choice reflects the fact
9 that these beliefs may be modifiable, potentially leading to changes in lifestyle.

10 Investigation of a patient's beliefs about lifestyle, and a dialogue about unwarranted
11 beliefs, may help modify behavior and improve health. For example, patients who
12 are convinced of the benefits of physical activity might adopt a regular exercise
13 routine. In addition, dispelling unwarranted fears about the risks of vaccination may
14 encourage patients to be vaccinated against infectious diseases.

15 In some cases, different groups of patients held opposing beliefs, such as those
16 relating to the impact of physical activity or diet on disease flares. For example, the
17 proportion of patients who believed that physical activity triggered their disease
18 flares (35.5%) was comparable to the proportion of those who held the opposite
19 opinion, that physical activity reduced their flares (36.5%). It should be noted,
20 however, that the two items are not wholly comparable, since they are phrased
21 somewhat differently: the deleterious belief referring to 'physical effort' (passive) and
22 the beneficial belief referring to 'doing sport or physical activity' (active).

23 Nevertheless, the characteristics of these two groups of patients were different:
24 those who considered physical activity to be detrimental were more frequently
25 anxious or depressed and expressed a high helplessness score, possibly indicating

1 that this belief was associated with psychological distress. In contrast, patients who
2 believed that physical activity was beneficial tended to be better educated, less
3 depressed, and to rate their disease activity as low. With respect to this particular
4 belief, it is noteworthy that medical opinion has evolved over recent years – whereas
5 in the 20th century many physicians had a conservative approach to exercise in
6 patients with CIRDs, a consensus has now emerged that exercise and sports
7 activities are helpful in the short- and long-term management of disease, which is
8 reflected in current practice guidelines [23, 24].

9 The study has a number of limitations that should be considered when interpreting
10 the results. Firstly, participation of rheumatologists was voluntary and not
11 remunerated, and physicians with a hospital practice were over-represented. This
12 may have influenced the representativeness of the patient sample included.
13 However, the age and gender distributions of enrolled patients were similar to those
14 of the overall RA [25] or axSpA [26] populations. Nevertheless, the proportion of
15 patients in this study who were undergoing treatment with biological DMARDs was
16 much higher than national figures (75%, versus 14% of all French RA patients [25]
17 and 26% of all axSpA patients [26]). Another factor to be considered in
18 interpretation of these data relates to the choice of the cut-off value for the
19 identification of 'strongly held' beliefs (≥ 7 on the VAS). This choice was purely
20 empirical and, in the absence of any known disease characteristic with which these
21 beliefs are correlated, we do not believe that it is realistic to attempt any
22 psychometric calibration of the VAS. Use of a threshold lower than 7 would clearly
23 generate higher percentages of 'believers'. Finally, it is important to note that the
24 items of the QuAD were derived from a qualitative survey of French patients [11]. It
25 is possible that patients in other countries or cultures would have different concerns
26 [27, 28], which would be interesting to evaluate in future studies.

1 We believe that exploring patient beliefs about disease and treatment with a
2 questionnaire such as the QuAD is useful for the physician in several ways; for
3 example, to facilitate dialogue with the patient and to help patients understand their
4 disease and form realistic treatment expectations. In particular, we believe that
5 physicians should discuss lifestyle beliefs with their patients in order to dissipate
6 unwarranted concerns and unfounded beliefs, and to encourage the adoption of
7 healthy lifestyles. Facilitating physician-patient dialogue in this way would be
8 expected to improve the overall quality of care, and to encourage the patient to
9 become an active partner in setting and achieving treatment goals. In addition, the
10 questionnaire may be a useful component of therapeutic education programs for
11 structuring debate about disease perceptions. Finally, patients may feel that their
12 perceptions and concerns about their disease are not considered important or
13 discussed by their physician, and the availability of the QuAD might help to address
14 this need. At a population level, the questionnaire could also describe shifts in beliefs
15 over time (following awareness campaigns, for example).

16 In conclusion, it is important to understand and discuss patients' beliefs about
17 inflammatory rheumatic diseases in order to optimize the quality of care. The QuAD
18 provides a simple tool to help achieve this, and merits further assessment.

19 **ETHICAL STATEMENT**

20 The study was performed in accordance with Good Epidemiological Practice [14] and
21 relevant French guidelines for patient surveys. Verbal informed consent was obtained
22 from all participating patients. The study protocol was considered by the Ethics
23 Committee of the St Antoine Hospital, Paris, to be both ethical and outside the scope
24 of French legislation restricting biomedical research (session of 7th October 2014).

25 The study was also declared to the National Advisory Committee on Medical

1 Research Information (CCTIRS) and the French national data protection agency
2 (CNIL).

3

4

1 REFERENCES

- 2 1. Lutze U, Archenholtz B (2007) The impact of arthritis on daily life with the
3 patient perspective in focus. *Scand J Caring Sci* 21:64–70.
- 4 2. Carr A, Hewlett S, Hughes R, Mitchell H, Ryan S, Carr M, Kirwan J (2003)
5 Rheumatology outcomes: the patient's perspective. *J Rheumatol* 30:880–883.
- 6 3. Goodacre LJ, Goodacre JA (2004) Factors influencing the beliefs of patients
7 with rheumatoid arthritis regarding disease-modifying medication. *Rheumatology*
8 (Oxford) 43:583–586.
- 9 4. Vriezekolk JE, van Lankveld WG, Geenen R, van den Ende CH (2011)
10 Longitudinal association between coping and psychological distress in rheumatoid
11 arthritis: a systematic review. *Ann Rheum Dis* 70:1243–1250.
- 12 5. Groarke A, Curtis R, Coughlan R, Gsel A (2004) The role of perceived and
13 actual disease status in adjustment to rheumatoid arthritis. *Rheumatology (Oxford)*
14 43:1142–1149.
- 15 6. Ehrlich-Jones L, Lee J, Semanik P, Cox C, Dunlop D, Chang RW (2011)
16 Relationship between beliefs, motivation, and worries about physical activity and
17 physical activity participation in persons with rheumatoid arthritis. *Arthritis Care Res*
18 (Hoboken) 63:1700–1705.
- 19 7. Salminen E, Heikkilä S, Poussa T, Lagström H, Saario R, Salminen S (2002)
20 Female patients tend to alter their diet following the diagnosis of rheumatoid arthritis
21 and breast cancer. *Prev Med* 34:529–535.
- 22 8. de Thurah A, Nørgaard M, Harder I, Stengaard-Pedersen K (2010)
23 Compliance with methotrexate treatment in patients with rheumatoid arthritis:
24 influence of patients' beliefs about the medicine. A prospective cohort study.
25 *Rheumatol Int* 30:1441–1448.
- 26 9. Nestoriuc Y, Orav EJ, Liang MH, Horne R, Barsky AJ (2010) Prediction of
27 nonspecific side effects in rheumatoid arthritis patients by beliefs about medicines.
28 *Arthritis Care Res (Hoboken)* 62:791–799.

- 1 10. Gossec L, Berenbaum F, Chauvin P, Lamiraud K, Russo-Marie F, Joubert JM,
2 Saraux A (2014) Reporting of patient-perceived impact of rheumatoid arthritis and
3 axial spondyloarthritis over 10 years: a systematic literature review. *Rheumatology*
4 (Oxford) 53:1274–1281.
- 5 11. Berenbaum F, Chauvin P, Hudry C, Mathoret-Philibert F, Poussière M, de
6 Chalus T, Dreuillet C, Russo-Marie F, Joubert JM, Saraux A (2014) Fears and beliefs
7 in rheumatoid arthritis and spondyloarthritis: a qualitative study. *PLoS One*
8 9:e114350.
- 9 12. Gossec L, Saraux A, Hudry C, Mathoret-Philibert F, Poussière M, de Chalus T,
10 Russo-Marie F, Joubert J, Chauvin P, Berenbaum F (2015) Development and
11 Validation of a Questionnaire Assessing the Fears and Beliefs of Patients Suffering
12 from Chronic Rheumatic Diseases. *Value Health* 18:A708.
- 13 13. Wild D, Grove A, Martin M, Eremenco S, McElroy S, Verjee-Lorenz A, Erikson
14 P (2005) Principles of Good Practice for the Translation and Cultural Adaptation
15 Process for Patient-Reported Outcomes (PRO) Measures: report of the ISPOR Task
16 Force for Translation and Cultural Adaptation. *Value Health* 8:94–104.
- 17 14. Council for International Organizations of Medical Sciences: International
18 ethical guidelines for epidemiological studies. Geneva: CIOMS;2008.
- 19 15. Aletaha D, Neogi T, Silman AJ (2010) 2010 Rheumatoid arthritis classification
20 criteria: an American College of Rheumatology/European League Against
21 Rheumatism collaborative initiative. *Ann Rheum Dis* 69:1580–1588.
- 22 16. Zeidler H, Amor B (2011) The Assessment in Spondyloarthritis International
23 Society (ASAS) classification criteria for peripheral spondyloarthritis and for
24 spondyloarthritis in general: the spondyloarthritis concept in progress. *Ann Rheum*
25 *Dis* 70:1–3.
- 26 17. Zigmond AS, Snaith RP (1983). The hospital anxiety and depression scale.
27 *Acta Psychiatr Scand* 67:361–370.

- 1 18. Nicassio PM, Wallston KA, Callahan LF, Herbert M, Pincus T (1985) The
2 measurement of helplessness in rheumatoid arthritis. The development of the
3 arthritis helplessness index. *J Rheumatol* 12:462–467.
- 4 19. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A (1994)
5 A new approach to defining disease status in ankylosing spondylitis: the Bath
6 Ankylosing Spondylitis Disease Activity Index. *J Rheumatol* 21:2286–2291.
- 7 20. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van
8 Riel PL (1995) Modified disease activity scores that include twenty-eight-joint counts.
9 Development and validation in a prospective longitudinal study of patients with
10 rheumatoid arthritis. *Arthritis Rheum* 38:44–48.
- 11 21. Gossec L, Chauvin P, Saraux A, Hudry C, Cukierman G, de Chalus T, Dreuillet
12 C, Saulot V, Tong S, Russo-Marie F, Joubert J-M, Berenbaum F (2017) Development
13 and psychometric validation of a patient-reported outcome measure to assess fears
14 in rheumatoid arthritis and axial spondyloarthritis: the Fear Assessment in
15 Inflammatory Rheumatic diseases (FAIR) questionnaire. *Ann Rheum Dis* 77:258–263.
- 16 22. Brown MA, Kenna T, Wordsworth BP (2016) Genetics of ankylosing
17 spondylitis--insights into pathogenesis. *Nat Rev Rheumatol* 12:81–91.
- 18 23. Gaujoux-Viala C, Gossec L, Cantagrel A, Dougados M, Fautrel B, Mariette X,
19 Nataf H, Saraux A, Trope S, Combe B; French Society for Rheumatology (2014)
20 Recommendations of the French Society for Rheumatology for managing rheumatoid
21 arthritis. *Joint Bone Spine* 81:287–297.
- 22 24. Braun J, van den Berg R, Baraliakos X, et al (2011) 2010 update of the
23 ASAS/EULAR recommendations for the management of ankylosing spondylitis. *Ann*
24 *Rheum Dis* 70:896–904.
- 25 25. Fautrel B, Cukierman G, Joubert JM, Laurendeau C, Gourmelen J, Fagnani F
26 (2016) Characteristics and management of rheumatoid arthritis in France: Analysis of
27 a representative French national claims database resulting in an estimated
28 prevalence of 0.35. *Joint Bone Spine* 83:461–462.

- 1 26. Claudepierre P, Breban M, de Chalus T, Joubert J, Laurendeau C, Gourmelen
2 J, Fagnani F (2015) Prevalence, Comorbidities and Burden of Severe
3 Spondyloarthritis In France: Analysis of A National Public Health Insurance Database
4 In 2012 In France. *Value Health* 18:A637.
- 5 27. Putrik P, Ramiro S, Hifinger M, Keszei AP, Hmamouchi I, Dougados M, Gossec
6 L, Boonen A (2016) In wealthier countries, patients perceive worse impact of the
7 disease although they have lower objectively assessed disease activity: results from
8 the cross-sectional COMORA study. *Ann Rheum Dis* 75:715–720.
- 9 28. Nikiphorou E, Radner H, Chatzidionysiou K, Desthieux C, Zabalán C, van Eijk-
10 Hustings Y, Dixon WG, Hyrich KL, Askling J, Gossec L (2016) Patient global
11 assessment in measuring disease activity in rheumatoid arthritis: a review of the
12 literature. *Arthritis Res Ther* 18:251.
- 13

1 **TABLES**

2

3 **Table 1** Patient characteristics

	RA [n= 432]	axSpA [n= 240]	TOTAL [N=672]
Age (years)	58.3 (13.1)	47.0 (13.2)	54.2 (14.2)
Gender (Women, %)	276 (74.0%)	94 (45.2%)	370 (63.7%)
Professional activity			
In employment	162 (38.2%)	167 (70.5%)	329 (49.8%)
Retired	201 (47.4%)	30 (12.7%)	231 (34.9%)
Other	61 (14.4%)	40 (16.8%)	101 (15.3%)
Education level			
Primary	77 (18.0%)	11 (4.6%)	88 (13.3%)
Secondary	219 (51.3%)	134 (56.3%)	353 (53.1%)
Tertiary (post-high school)	131 (30.7%)	93 (39.1%)	224 (33.7%)
Disease duration (years)	13.1 (11.4)	13.8 (10.6)	13.4 (11.1)
Disease activity			
DAS28(ESR)	2.6 (1.2)	-	-
BASDAI	-	3.3 (2.2)	-
Physician global assessment (0–10)	2.75 (2.12)	3.44 (2.41)	3.00 (2.25)
Patient global assessment (0–10)	3.03 (2.45)	4.27 (2.61)	3.48 (2.58)
Treatments			
Corticosteroids alone	6 (1.8%)	-	6 (1.1%)
NSAIDs alone	-	36 (15.1%)	36 (6.4%)
Synthetic DMARDs ± corticosteroids/ NSAIDs	61 (18.7%)	15 (6.3%)	76 (13.5%)
Biological DMARDs (alone or in combination)	252 (77.3%)	173 (72.7%)	425 (75.4%)
Other	2 (0.6%)	7 (2.9%)	9 (0.7%)

4 Data are presented as mean values (standard deviation) for continuous variables, and as
5 frequency counts (%) for categorical variables. Data were missing for some patients for all
6 variables. axSpA: axial spondyloarthritis; BASDAI: Bath Ankylosing Spondylitis Disease Activity
7 Index; DAS28(ESR): 28-item disease activity score measured with erythrocyte sedimentation
8 rate; DMARD: disease-modifying anti-rheumatic drug; NSAID: non-steroidal anti-
9 inflammatory drug; RA: rheumatoid arthritis.

10

1 **Table 2** The QuAD questionnaire and mean scores for each item in patients with RA
 2 or axSpA

QuAD Item		RA n=432	axSpA n=240	TOTAL N=672
	Psychological factors			
P1	I think that my disease was triggered by an emotional shock. (A difficult or stressful period in my life).	5.1 (3.9)	3.6 (3.8)	4.6 (3.9)
P2	I think that flare-ups of my disease are triggered by psychological factors (stress, upset, low morale, etc.).	4.6 (3.5)	4.7 (3.3)	4.7 (3.4)
	Genetic factors			
G1	I think that my disease has a genetic cause.	4.0 (3.6)	6.6 (3.5)	5.0 (3.8)
G2	I am afraid of passing my disease on to my children.	4.7 (4.1)	6.8 (3.7)	5.5 (4.1)
	Physical activity			
F1	I think that my disease was triggered by physical overload.	2.9 (3.3)	3.1 (3.3)	3.0 (3.3)
F2	I think that flare-ups of my disease are triggered by physical effort.	4.2 (3.5)	5.4 (3.2)	4.6 (3.4)
F3	I think that my flare-ups are triggered by bad posture or staying in the same position for too long.	3.2 (3.3)	5.7 (3.3)	4.1 (3.5)
F4	I think that doing sport or a physical activity reduces my flare-ups.	4.5 (3.3)	5.9 (3.0)	5.0 (3.3)
	Diet			
D1	I think that my disease may have been triggered by what I ate.	1.3 (2.3)	1.3 (2.3)	1.3 (2.3)
D2	I think that drinking alcohol (even moderately) triggered my disease.	0.7 (1.7)	0.5 (1.4)	0.7 (1.6)
D3	I think that eating certain foods triggers my flare-ups.	2.1 (2.9)	2.0 (2.7)	2.0 (2.8)
D4	I think that eating certain foods reduces my flare-ups.	2.2 (3.0)	1.9 (2.7)	2.1 (2.9)
	Other lifestyle factors			
O1	I think that my flare-ups are triggered by fatigue.	4.9 (3.4)	5.8 (3.1)	5.2 (3.3)
O2	I think that smoking (even moderately) or being exposed to passive smoking triggered my disease.	1.5 (2.5)	1.0 (1.8)	1.3 (2.3)
O3	I think that my disease was triggered by something in the environment, like pollution.	1.6 (2.5)	1.3 (2.4)	1.5 (2.5)
	Miscellaneous			
M1	I think that my flare-ups are triggered by a change in the weather.	4.3 (3.4)	5.1 (3.4)	4.6 (3.4)
M2	I think that my disease was triggered by a vaccination.	1.4 (2.7)	1.3 (2.7)	1.3 (2.7)
M3	I think that my disease was triggered by an infection.	1.7 (2.7)	1.7 (2.7)	1.7 (2.7)
M4	I think that some types of alternative medicine (osteopathy, acupuncture, sophrology, homeopathy, etc.) reduce my flare-ups.	3.5 (3.4)	3.8 (3.3)	3.6 (3.3)
M5	I think that all treatments have negative effects in the long term.	4.9 (3.5)	5.4 (3.1)	5.1 (3.4)
M6	I don't know how my disease will progress (and that worries me).	5.9 (3.2)	7.0 (3.1)	6.3 (3.2)

3 Scores are presented as mean scores (standard deviation) on a scale from 0–10, where 10
 4 indicates full agreement. axSpA: axial spondyloarthritis; QuAD: Questionnaire for Arthritis
 5 Dialogue; RA: rheumatoid arthritis.

- 1 **Table 3** Principal associations between patient variables and strongly held beliefs
 2 (QuAD score ≥ 7)

	QuAD Item	Patient variable	Reference		OR [95% CI]
F4	Physical activity reduces flares	Diagnosis	RA	axSpA	2.15 [1.50–3.08]
O2	Disease caused by smoking	Diagnosis	RA	axSpA	0.60 [0.36–0.96]
D4	Certain foods reduce flares	Gender	Men	Women	2.22 [1.18–4.20]
F1	Disease caused by physical overload	Education	Higher	High school	2.14 [1.30–3.53]
F4	Physical activity reduces flares	Education	Higher	High school	0.42 [0.29–0.60]
O2	Disease caused by smoking	Social deprivation	Not deprived	Deprived	2.04 [1.15–3.62]
D2	Disease caused by alcohol	Social deprivation	Not deprived	Deprived	4.18 [1.19–14.6]
F1	Disease caused by physical overload	Anxiety	HADS-A ≤ 8	HADS-A > 10	2.87 [1.67–4.92]
F2	Flares triggered by physical effort	Anxiety	HADS-A ≤ 8	HADS-A > 10	1.59 [1.03–2.45]
F4	Physical activity reduces flares	Depression	HADS-D ≤ 8	HADS-D > 18	0.58 [0.38–0.88]
F2	Flares triggered by physical effort	Depression	HADS-D ≤ 8	HADS-D > 8	1.49 [1.00–2.23]
F2	Flares triggered by physical effort	Helplessness	AHI < 20	AHI ≥ 20	1.77 [1.23–2.54]
O3	Disease caused by environmental factor	Helplessness	AHI < 20	AHI ≥ 20	2.93 [1.38–6.18]

- 3 The codes for the questionnaire items correspond to those listed in **Table 2**. Data are
 4 presented as odds ratios (OR) with 95% confidence intervals (CI). AHI: Arthritis Helplessness
 5 Index; axSpA: axial spondyloarthritis; HADS: Hospital Anxiety and Depression Scale; QuAD:
 6 Questionnaire for Arthritis Dialogue; RA: rheumatoid arthritis.

7

1 **FIGURE LEGENDS**

2 **Fig. 1** Proportion of patients with strongly held beliefs (QuAD score ≥ 7)

3 The codes for the questionnaire items correspond to those listed in **Table 2**.

4 □: patients with RA (n=432); ■: patients with axSpA (n=240).

5 QuAD: Questionnaire for Arthritis Dialogue.